<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pneumonia caused by &lt;i&gt;Chlamydia pneumoniae&lt;/i&gt; in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pneumonia caused by
       <i>
        Chlamydia pneumoniae
       </i>
       in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pneumonia caused by
        <i>
         Chlamydia pneumoniae
        </i>
        in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jesus G Vallejo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert A Wood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumonia caused by
         <em>
          Chlamydia pneumoniae
         </em>
         in children will be discussed here. Infections caused by other species of
         <em>
          Chlamydia
         </em>
         and community-acquired pneumonia in children are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">
          "Chlamydia trachomatis infections in the newborn"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">
          "Clinical manifestations and diagnosis of
          <i>
           Chlamydia trachomatis
          </i>
          infections"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">
          "Treatment of
          <i>
           Chlamydia trachomatis
          </i>
          infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7015.html" rel="external">
          "Psittacosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">
          "Pneumonia in children: Epidemiology, pathogenesis, and etiology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. pneumoniae
         </em>
         is an obligate intracellular pathogen that belongs to the Chlamydiaceae family and
         <em>
          Chlamydia
         </em>
         genus [
         <a href="#rid1">
          1
         </a>
         ]. Although there was a proposal to divide the
         <em>
          Chlamydia
         </em>
         genus into two genera,
         <em>
          Chlamydia
         </em>
         and
         <em>
          Chlamydophila
         </em>
         [
         <a href="#rid2">
          2
         </a>
         ], an international committee on the taxonomy of Chlamydiae agreed that the Chlamydiaceae family contains a single genus,
         <em>
          Chlamydia
         </em>
         [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         <em>
          Chlamydia
         </em>
         spp are unusual in several ways. Their genome is smaller than that of any other prokaryote except
         <em>
          Mycoplasma
         </em>
         . Their cell wall contains very small amounts of peptidoglycan [
         <a href="#rid4">
          4
         </a>
         ]. Their growth cycle is complex and biphasic, consisting of two distinct forms [
         <a href="#rid5">
          5-7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elementary bodies – Elementary bodies are the infectious form. They can survive in the extracellular environment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticulate bodies – Reticulate bodies are the form in which
         <em>
          C. pneumoniae
         </em>
         replicates within a membrane-bound inclusion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H521130182">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. pneumoniae
         </em>
         is a common respiratory pathogen [
         <a href="#rid7">
          7,8
         </a>
         ].
         <em>
          C. pneumoniae
         </em>
         pneumonia occurs worldwide [
         <a href="#rid9">
          9
         </a>
         ]. Outbreaks in closed populations (eg, schools, military recruits, nursing homes) have been described [
         <a href="#rid10">
          10-13
         </a>
         ].
        </p>
        <p>
         In case series of children with community-acquired pneumonia, the proportion of cases associated with
         <em>
          C. pneumoniae
         </em>
         varies from study to study, ranging from 0.3 to 44 percent, depending upon the diagnostic method and population studied [
         <a href="#rid7">
          7,14-20
         </a>
         ]. When culture or polymerase chain reaction (PCR)-based assays were used, the proportion ranged from 0.3 to 7.8 percent [
         <a href="#rid7">
          7,17,19,20
         </a>
         ]. Epidemiologic studies that used serology for diagnosis of
         <em>
          C. pneumoniae
         </em>
         must be interpreted with caution. Serology has poor correlation with culture and PCR [
         <a href="#rid7">
          7,9,21-23
         </a>
         ]. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         The initial infection typically occurs between 5 and 15 years of age but may occur earlier in tropical and resource-limited countries [
         <a href="#rid21">
          21,24,25
         </a>
         ]. In the United States, approximately 30 percent of adolescents younger than 20 years are seropositive for
         <em>
          C. pneumoniae
         </em>
         [
         <a href="#rid24">
          24
         </a>
         ], although patients with culture-documented
         <em>
          C. pneumoniae
         </em>
         infection, particularly children younger than five years, may not develop antibodies [
         <a href="#rid9">
          9,26-31
         </a>
         ].
        </p>
        <p>
         <em>
          C. pneumoniae
         </em>
         is thought to be transmitted from person to person via respiratory tract secretions [
         <a href="#rid25">
          25
         </a>
         ]. It is shed from the respiratory tract during acute illness and for as long as one year after [
         <a href="#rid26">
          26
         </a>
         ]. Whether symptoms increase the risk of transmission is unclear [
         <a href="#rid8">
          8
         </a>
         ]. The mean incubation period is 21 days [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Coinfection with other pathogens, including
         <em>
          Streptococcus
         </em>
         <em>
          pneumoniae
         </em>
         ,
         <em>
          Mycoplasma pneumoniae
         </em>
         , and viruses, is common [
         <a href="#rid14">
          14,21,32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         At the onset
         <em>
          of C. pneumoniae
         </em>
         infection, elementary bodies (EBs), the infectious form of
         <em>
          C. pneumoniae
         </em>
         , attach to respiratory mucosal epithelial cells and enter the cells via a phagosome. Once inside the cell, EBs reorganize to reticulate bodies (RBs), which then replicate, forming intracytoplasmic inclusions. RBs are unstable and revert to EBs, which are released through cell lysis or exocytosis and go on to infect other cells [
         <a href="#rid5">
          5,7
         </a>
         ]. When
         <em>
          C. pneumoniae
         </em>
         is involved in coinfections, it may disrupt normal clearance mechanisms, allowing the other pathogen to invade [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The host immune response is induced by chlamydial antigens, which are released onto the host cell surface during replication [
         <a href="#rid5">
          5
         </a>
         ]. Because immunity is short-lived, reinfection or persistent infection is possible [
         <a href="#rid5">
          5,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical features of
         <em>
          C. pneumoniae
         </em>
         pneumonia are similar to those of other types of community-acquired pneumonia (CAP) and include fever, cough, tachypnea, and shortness of breath [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         No clinical, laboratory, or radiographic findings reliably differentiate
         <em>
          C. pneumoniae
         </em>
         pneumonia from other causes of CAP [
         <a href="#rid21">
          21,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         <em>
          C. pneumoniae
         </em>
         infection is frequently asymptomatic or only mildly symptomatic  (
         <a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid35">
          35
         </a>
         ]. However, severe and life-threatening infections can occur [
         <a href="#rid36">
          36,37
         </a>
         ]. Coinfection with other pathogens may affect the clinical presentation [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         In small case series, common features of
         <em>
          C. pneumoniae
         </em>
         pneumonia include gradual onset of symptoms, associated pharyngitis, and often hoarseness  (
         <a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid21">
          21,39,40
         </a>
         ]. Sinusitis frequently accompanies
         <em>
          C. pneumoniae
         </em>
         pneumonia or develops as a complication. Pneumonia caused by
         <em>
          Mycoplasma
         </em>
         spp and respiratory viruses can present in a similar fashion.
        </p>
        <p>
         The white blood cell count is usually normal or mildly elevated [
         <a href="#rid33">
          33
         </a>
         ]. Chest radiograph findings generally are nonspecific and include patchy subsegmental infiltration, bilateral infiltrates, and pleural effusion [
         <a href="#rid21">
          21,33,36
         </a>
         ].
        </p>
        <p>
         Although there are rare reports of extrapulmonary manifestations (eg, meningoencephalitis [
         <a href="#rid41">
          41-43
         </a>
         ], Guillain-Barré syndrome [
         <a href="#rid44">
          44
         </a>
         ], and myocarditis [
         <a href="#rid45">
          45-49
         </a>
         ]), a causal role for
         <em>
          C. pneumoniae
         </em>
         has not been definitively established.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for laboratory evaluation
         </strong>
         – We individualize decisions about laboratory testing for
         <em>
          C. pneumoniae
         </em>
         based upon severity of illness, test availability, and whether the results would affect management (eg, to provide specific therapy in critically ill children). General indications for microbiologic testing in children with community-acquired pneumonia (CAP) are discussed separately (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Indications for microbiologic testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We usually perform laboratory evaluation for
         <em>
          C. pneumoniae
         </em>
         only
         <em>
         </em>
         in hospitalized children who are critically ill and require mechanical ventilation; the sample is obtained from a tracheal aspirate or bronchoalveolar lavage. Our institution does not have an in-house multiplex respiratory panel that includes
         <em>
          C. pneumoniae
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Testing is rarely necessary in the outpatient setting, where empiric therapy with activity against
         <em>
          C. pneumoniae
         </em>
         typically is initiated in children ≥5 years with CAP and clinical features suggestive of atypical pneumonia  (
         <a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">
          "Community-acquired pneumonia in children: Outpatient treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">
          "Community-acquired pneumonia in children: Outpatient treatment", section on 'Factors influencing choice of regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiologic confirmation
         </strong>
         – When confirmation of
         <em>
          C. pneumoniae
         </em>
         is necessary, polymerase chain reaction (PCR)-based assays are preferred if available [
         <a href="#rid23">
          23,50
         </a>
         ]. Cell culture is an alternative, but results will not be available to guide initial treatment. Serology is not helpful in the diagnosis of acute
         <em>
          C. pneumoniae
         </em>
         infection. (See
         <a class="local">
          'Antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          PCR-based assays
         </strong>
         – PCR-based assays have high sensitivity and specificity and provide rapid results [
         <a href="#rid9">
          9,23
         </a>
         ]. However, positive results for
         <em>
          C. pneumoniae
         </em>
         should be correlated with clinical findings because PCR-based assays do not differentiate between acute symptomatic infection and asymptomatic infection or persistent
         <em>
          C. pneumoniae
         </em>
         following resolution of symptoms [
         <a href="#rid21">
          21,26,51
         </a>
         ]. Identification of
         <em>
          C. pneumoniae
         </em>
         does not exclude coinfection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         PCR-based assays can be performed on a variety of respiratory specimens (eg, nasopharyngeal swab or aspirate, oropharyngeal swab, bronchial lavage fluid). However, the sensitivity and specificity of most PCR-based assays, including multiplex assays, when used on different clinical samples and in the clinical setting are unknown. Pending additional information, results of PCR-based assays should be used in conjunction with clinical and epidemiologic information to make treatment decisions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Availability of PCR-based assays for
         <em>
          C. pneumoniae
         </em>
         vary from laboratory to laboratory. Clinicians should check with their laboratory for details about appropriate specimen types, specimen collection, and transport [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Commercially available multiplex panels for respiratory infection that include
         <em>
          C. pneumoniae
         </em>
         are used by some institutions and general practitioners in the evaluation of patients with respiratory tract infections [
         <a href="#rid52">
          52-56
         </a>
         ]. If the panel is sent to an outside laboratory, turnaround time is usually one to three days; if it is performed on site, turnaround time is usually three to four hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cell culture
         </strong>
         – Although cell culture permits genotyping and antimicrobial susceptibility testing, it is rarely used for routine clinical testing because it requires specialized techniques with variable sensitivity and specificity depending on the expertise of the laboratory and can take weeks to obtain results [
         <a href="#rid7">
          7,9,23
         </a>
         ]. It is not widely available and is costly.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serology
         </strong>
         – Serology is not helpful in the diagnosis of acute
         <em>
          C. pneumoniae
         </em>
         infection. It is not standardized, has poor correlation with culture and PCR, and requires collection of both acute and convalescent sera for diagnosis [
         <a href="#rid7">
          7,9,21-23,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          ANTIMICROBIAL THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H2257089426">
         <span class="h2">
          Empiric therapy for community-acquired pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for community-acquired pneumonia (CAP) in children usually is initiated empirically, based upon the age of the child and the clinical presentation. Among children who are treated as outpatients, microbiologic testing generally is not obtained. Empiric therapy may or may not include coverage for atypical pathogens, including
         <em>
          C. pneumoniae
         </em>
         . If
         <em>
          C. pneumoniae
         </em>
         is suspected (eg, outbreak setting, clinical features suggestive of atypical pathogens  (
         <a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">
          table 2
         </a>
         )), empiric therapy should include activity against
         <em>
          C. pneumoniae
         </em>
         (eg, a macrolide antibiotic with or without additional coverage for typical bacterial pathogens). Empiric therapy for CAP in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">
          "Community-acquired pneumonia in children: Outpatient treatment", section on 'Empiric therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">
          "Pneumonia in children: Inpatient treatment", section on 'Empiric therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">
          "Community-acquired pneumonia in children: Outpatient treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H284934173">
         <span class="h2">
          Therapy for
          <i>
           C. pneumoniae
          </i>
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outpatient setting
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preferred regimen – For children with microbiologically confirmed
         <em>
          C. pneumoniae
         </em>
         pneumonia in the outpatient setting, we suggest treatment with
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         10 mg/kg per day orally (maximum daily dose 500 mg) on day 1 followed by 5 mg/kg per day orally (maximum daily dose 250 mg) on days 2 through 5.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alternative regimen –
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          Doxycycline
         </a>
         2 to 4 mg/kg per day orally divided into two doses (maximum daily dose 200 mg) for seven days is an alternative for children of all ages [
         <a href="#rid58">
          58-60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We prefer
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         because its treatment course is shorter and it is associated with fewer adverse effects than other oral agents with activity against
         <em>
          C. pneumoniae
         </em>
         (eg, other macrolides,
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">
          moxifloxacin
         </a>
         ) [
         <a href="#rid61">
          61-64
         </a>
         ]. Fluoroquinolones generally are reserved for children in whom there is no safe and effective alternative or an oral fluoroquinolone is the only alternative to parenteral therapy [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospitalized children
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preferred regimen – For children who require hospitalization for severe microbiologically confirmed
         <em>
          C. pneumoniae
         </em>
         pneumonia  (
         <a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">
          table 1
         </a>
         ), we suggest initial treatment with
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         10 mg/kg intravenously (IV) once per day on day 1 and day 2, followed by transition to oral therapy (if possible) with azithromycin 5 mg/kg orally once per day to complete a five-day course [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alternative regimens – Alternative initial IV regimens include [
         <a href="#rid58">
          58
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          Erythromycin
         </a>
         20 mg/kg per day IV divided in four doses, or
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         – Age 6 months to 5 years: 16 to 20 mg/kg per day IV divided in two doses; age 5 to 16 years: 8 to 10 mg/kg per day IV once per day (maximum daily dose 750 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When the child is ready to transition to oral therapy, one of the following regimens can be used to complete a 7- to 10-day course of therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          Clarithromycin
         </a>
         15 mg/kg per day orally divided in two doses
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          Erythromycin
         </a>
         50 mg/kg per day orally divided in four doses
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          Doxycycline
         </a>
         2 to 4 mg/kg per day orally divided in two doses (maximum daily dose 200 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         500 mg orally once daily (for skeletally mature adolescents)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">
          Moxifloxacin
         </a>
         400 mg orally once daily (for skeletally mature adolescents)
        </p>
        <p>
        </p>
        <p>
         Clinical trials directly evaluating the efficacy of antibiotics on clinical outcomes in children with
         <em>
          C. pneumoniae
         </em>
         pneumonia are lacking. However, in randomized trials and observational studies of children with radiographically confirmed CAP,
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         appear to have clinical efficacy similar to that of
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         [
         <a href="#rid14">
          14,63,66,67
         </a>
         ].
        </p>
        <p>
         Although it is not known whether microbiologic eradication is necessary for clinical cure, in subgroup analysis of patients with culture-confirmed
         <em>
          C. pneumoniae
         </em>
         from several clinical trials, the efficacy of microbiologic eradication was approximately 80 percent with a 5-day course of
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid63">
          63,68
         </a>
         ] and 70 to 100 percent with a 10-day course of
         <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">
          moxifloxacin
         </a>
         or a 7- to 10-day course of
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         [
         <a href="#rid28">
          28,69,70
         </a>
         ]. Failures are thought to be due to lack of eradication of the pathogen in its persistent state and not due to drug resistance [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3262785259">
         <span class="h1">
          RESPONSE TO THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with community-acquired pneumonia who receive appropriate antimicrobial therapy generally are clinically improved within 48 to 72 hours of treatment. Management of those who do not improve as expected is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">
          "Community-acquired pneumonia in children: Outpatient treatment", section on 'Treatment failure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">
          "Pneumonia in children: Inpatient treatment", section on 'Treatment failure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H508799185">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. pneumoniae
         </em>
         pneumonia is usually mild and most patients recover without complications [
         <a href="#rid8">
          8
         </a>
         ]. In some children,
         <em>
          C. pneumoniae
         </em>
         may be associated with prolonged cough (mean duration 25 to 30 days) [
         <a href="#rid8">
          8,72-75
         </a>
         ]. Although
         <em>
          C. pneumoniae
         </em>
         has been associated with asthma [
         <a href="#rid76">
          76-79
         </a>
         ] and reactive arthritis [
         <a href="#rid80">
          80-82
         </a>
         ], a causal relationship has not been established.
        </p>
        <p class="headingAnchor" id="H3530739371">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. pneumoniae
         </em>
         is thought to be transmitted from person to person via respiratory tract secretions or fomites. Frequent hand washing and respiratory hygiene/cough etiquette are suggested to prevent transmission [
         <a href="#rid12">
          12,25,83
         </a>
         ].
        </p>
        <p>
         For patients hospitalized with
         <em>
          C. pneumoniae
         </em>
         pneumonia or community-acquired pneumonia of unknown etiology, standard precautions are recommended [
         <a href="#rid25">
          25,84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H629218448">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110776.html" rel="external">
          "Society guideline links: Pediatric pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8578490">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17120.html" rel="external">
          "Patient education: Pneumonia in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Chlamydia pneumoniae
         </em>
         is an obligate intracellular pathogen that causes a minority of cases of community-acquired pneumonia (CAP) in children. Outbreaks have been reported in closed populations. Coinfection with other pathogens is common. The initial infection usually occurs between 5 and 15 years of age but may occur earlier. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical features of
         <em>
          C. pneumoniae
         </em>
         are similar to those of other types of CAP and include fever, cough, tachypnea, and shortness of breath. Common features include gradual onset of symptoms, associated pharyngitis, and often hoarseness  (
         <a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">
          table 2
         </a>
         ). However, no clinical, laboratory, or radiographic findings reliably differentiate
         <em>
          C. pneumoniae
         </em>
         pneumonia from other causes of CAP. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We individualize decisions about laboratory testing for
         <em>
          C. pneumoniae
         </em>
         based upon severity of illness, test availability, and whether the results would affect management (eg, to provide specific therapy in critically ill children). Testing is rarely necessary in the outpatient setting. When confirmation of
         <em>
          C. pneumoniae
         </em>
         is necessary, polymerase chain reaction-based assays are preferred if available. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with microbiologically confirmed
         <em>
          C. pneumoniae
         </em>
         pneumonia and clinical findings compatible with CAP, we suggest treatment with
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         rather than other macrolides, tetracyclines, or fluoroquinolones (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Azithromycin has a shorter treatment course and is associated with fewer adverse effects than other available agents. We use 10 mg/kg per day orally (maximum daily dose 500 mg) on day 1 followed by 5 mg/kg per day orally (maximum daily dose 250 mg) on days 2 through 5.
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          Doxycycline
         </a>
         is an alternative for children of all ages. (See
         <a class="local">
          'Therapy for C. pneumoniae'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children with CAP who receive appropriate antimicrobial therapy generally are clinically improved within 48 to 72 hours of treatment. Most patients recover without complications. (See
         <a class="local">
          'Response to therapy'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4090638389">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Dori Zaleznik, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          National Center for Biotechnology InformationTaxonomy Browser. Accessed May 10, 2017. https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=83558&amp;lvl=3&amp;lin=f&amp;keep=1&amp;srchmode=1&amp;unlock.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everett KD, Bush RM, Andersen AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. Int J Syst Bacteriol 1999; 49 Pt 2:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greub G. International Committee on Systematics of Prokaryotes Subcommittee on the taxonomy of Chlamydiae. Minutes of the closed meeting, 31 March 2015, New Orleans, USA. Int J Syst Evol Microbiol 2017; 67:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacquier N, Viollier PH, Greub G. The role of peptidoglycan in chlamydial cell division: towards resolving the chlamydial anomaly. FEMS Microbiol Rev 2015; 39:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burillo A, Bouza E. Chlamydophila pneumoniae. Infect Dis Clin North Am 2010; 24:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roulis E, Polkinghorne A, Timms P. Chlamydia pneumoniae: modern insights into an ancient pathogen. Trends Microbiol 2013; 21:120.
          </a>
         </li>
         <li class="breakAll">
          Hammerschlag MR, Kohlhoff SA. Chlamydia infections. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison G, Kaplan SL, et al (Eds), Elsevier, Philadelphia 2018. p.1952.
         </li>
         <li class="breakAll">
          Shah S. Chlamydophila (Chlamydia) pneumononiae. In: Principles and Practice of Pediatric Infectious Diseases, 5th, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.906.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fajardo KA, Zorich SC, Voss JD, Thervil JW. Pneumonia Outbreak Caused by Chlamydophila pneumoniae among US Air Force Academy Cadets, Colorado, USA. Emerg Infect Dis 2015; 21:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakashima K, Tanaka T, Kramer MH, et al. Outbreak of Chlamydia pneumoniae infection in a Japanese nursing home, 1999-2000. Infect Control Hosp Epidemiol 2006; 27:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conklin L, Adjemian J, Loo J, et al. Investigation of a Chlamydia pneumoniae outbreak in a Federal correctional facility in Texas. Clin Infect Dis 2013; 57:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt SM, Muller CE, Mahner B, Wiersbitzky SK. Prevalence, rate of persistence and respiratory tract symptoms of Chlamydia pneumoniae infection in 1211 kindergarten and school age children. Pediatr Infect Dis J 2002; 21:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999; 18:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurz H, Göpfrich H, Wabnegger L, Apfalter P. Role of Chlamydophila pneumoniae in children hospitalized for community-acquired pneumonia in Vienna, Austria. Pediatr Pulmonol 2009; 44:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Valle-Mendoza J, Orellana-Peralta F, Marcelo-Rodríguez A, et al. High Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in Children with Acute Respiratory Infections from Lima, Peru. PLoS One 2017; 12:e0170787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jantos CA, Wienpahl B, Schiefer HG, et al. Infection with Chlamydia pneumoniae in infants and children with acute lower respiratory tract disease. Pediatr Infect Dis J 1995; 14:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Principi N, Esposito S, Blasi F, et al. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis 2001; 32:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chirgwin K, Roblin PM, Gelling M, et al. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis 1991; 163:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuuminen T, Palomäki P, Paavonen J. The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Methods 2000; 42:265.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention (CDC) Chlaymida pneumoniae Infection: Diagnostic Methods https://www.cdc.gov/pneumonia/atypical/cpneumoniae/hcp/diagnostic.html (Accessed on May 12, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dal Molin G, Longo B, Not T, et al. A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren. J Clin Pathol 2005; 58:617.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Chlamydia pneumoniae. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.256.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyman CL, Augenbraun MH, Roblin PM, et al. Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR. J Clin Microbiol 1991; 29:2082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldous MB, Grayston JT, Wang SP, Foy HM. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis 1992; 166:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falck G, Gnarpe J, Gnarpe H. Prevalence of Chlamydia pneumoniae in healthy children and in children with respiratory tract infections. Pediatr Infect Dis J 1997; 16:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Normann E, Gnarpe J, Gnarpe H, Wettergren B. Chlamydia pneumoniae in children with acute respiratory tract infections. Acta Paediatr 1998; 87:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 1994; 148:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thom DH, Grayston JT, Wang SP, et al. Chlamydia pneumoniae strain TWAR, Mycoplasma pneumoniae, and viral infections in acute respiratory disease in a university student health clinic population. Am J Epidemiol 1990; 132:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puljiz I, Kuzman I, Dakovic-Rode O, et al. Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles. Epidemiol Infect 2006; 134:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           File TM Jr, Plouffe JF Jr, Breiman RF, Skelton SK. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis 1999; 29:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleemola M, Saikku P, Visakorpi R, et al. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis 1988; 157:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Augenbraun MH, Roblin PM, Mandel LJ, et al. Chlamydia pneumoniae pneumonia with pleural effusion: diagnosis by culture. Am J Med 1991; 91:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenenbaum T, Heusch A, Henrich B, et al. Acute hemorrhagic pericarditis in a child with pneumonia due to Chlamydophila pneumoniae. J Clin Microbiol 2005; 43:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyashita N, Fukano H, Okimoto N, et al. Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults. Chest 2002; 121:1776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grayston JT, Aldous MB, Easton A, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 1993; 168:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekman MR, Grayston JT, Visakorpi R, et al. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin Infect Dis 1993; 17:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anton E, Otegui A, Alonso A. Meningoencephalitis and Chlamydia pneumoniae infection. Eur J Neurol 2000; 7:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guglielminotti J, Lellouche N, Maury E, et al. Severe meningoencephalitis: an unusual manifestation of Chlamydia pneumoniae infection. Clin Infect Dis 2000; 30:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Socan M, Beovic B, Kese D. Chlamydia pneumonia and meningoencephalitis. N Engl J Med 1994; 331:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haidl S, Ivarsson S, Bjerre I, Persson K. Guillain-Barré syndrome after Chlamydia pneumoniae infection. N Engl J Med 1992; 326:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suesaowalak M, Cheung MM, Tucker D, et al. Chlamydophila pneumoniae myopericarditis in a child. Pediatr Cardiol 2009; 30:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durel CA, Saison J, Chidiac C, Ferry T. A case of interstitial pneumonia, myocarditis and severe sepsis caused by Chlamydia pneumoniae. BMJ Case Rep 2015; 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walder G, Gritsch W, Wiedermann CJ, et al. Co-infection with two Chlamydophila species in a case of fulminant myocarditis. Crit Care Med 2007; 35:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoefer D, Poelzl G, Kilo J, et al. Early detection and successful therapy of fulminant chlamydia pneumoniae myocarditis. ASAIO J 2005; 51:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong CY, Potter F, Worthington E, Mullins P. Chlamydia pneumoniae myocarditis. Lancet 1995; 346:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma L, Losier A, Tolbert T, et al. Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia. Clin Chest Med 2017; 38:45.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Devices@FDA. Available at: https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm (Accessed on March 26, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leber AL, Everhart K, Daly JA, et al. Multicenter Evaluation of BioFire FilmArray Respiratory Panel 2 for Detection of Viruses and Bacteria in Nasopharyngeal Swab Samples. J Clin Microbiol 2018; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee BR, Hassan F, Jackson MA, Selvarangan R. Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections. J Clin Virol 2019; 110:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babady NE, England MR, Jurcic Smith KL, et al. Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs. J Clin Microbiol 2018; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonsalves S, Mahony J, Rao A, et al. Multiplexed detection and identification of respiratory pathogens using the NxTAG® respiratory pathogen panel. Methods 2019; 158:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaydos CA, Roblin PM, Hammerschlag MR, et al. Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 1994; 32:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Tetracyclines. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.866.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Same RG, Amoah J, Hsu AJ, et al. The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children. J Pediatric Infect Dis Soc 2021; 10:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohlhoff SA, Hammerschlag MR. Treatment of Chlamydial infections: 2014 update. Expert Opin Pharmacother 2015; 16:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohlhoff SA, Huerta N, Hammerschlag MR. In Vitro Activity of Omadacycline against Chlamydia pneumoniae. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langley JM, Halperin SA, Boucher FD, et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:e96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numazaki K, Sakamoto Y, Umetsu M, et al. Therapeutic effect of clarithromycin for respiratory-tract infections in children caused by Chlamydia pneumoniae. Research Group of Sapporo for Pediatric Chlamydial Infections. Int J Antimicrob Agents 2000; 13:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee PI, Wu MH, Huang LM, et al. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. J Microbiol Immunol Infect 2008; 41:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 1998; 42:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000; 15:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother 2000; 44:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panzetta ME, Valdivia RH, Saka HA. Chlamydia Persistence: A Survival Strategy to Evade Antimicrobial Effects in-vitro and in-vivo. Front Microbiol 2018; 9:3101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallander HO, Gnarpe J, Gnarpe H, Olin P. Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae and persistent cough in children. Scand J Infect Dis 1999; 31:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jama-Kmiecik A, Frej-Madrzak M, Gosciniak G, et al. Detection of Chlamydophila Pneumoniae and Typical Bacteria in Patients with Chronic Cough. Adv Exp Med Biol 2015; 857:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagiwara K, Ouchi K, Tashiro N, et al. An epidemic of a pertussis-like illness caused by Chlamydia pneumoniae. Pediatr Infect Dis J 1999; 18:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright SW, Edwards KM, Decker MD, et al. Prevalence of positive serology for acute Chlamydia pneumoniae infection in emergency department patients with persistent cough. Acad Emerg Med 1997; 4:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juvonen R, Bloigu A, Paldanius M, et al. Acute Chlamydia pneumoniae infections in asthmatic and non-asthmatic military conscripts during a non-epidemic period. Clin Microbiol Infect 2008; 14:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asner SA, Jaton K, Kyprianidou S, et al. Chlamydia pneumoniae: possible association with asthma in children. Clin Infect Dis 2014; 58:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith-Norowitz TA, Chotikanatis K, Weaver D, et al. Chlamydia pneumoniae-induced tumour necrosis factor alpha responses are lower in children with asthma compared with non-asthma. BMJ Open Respir Res 2018; 5:e000239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dzhindzhikhashvili MS, Joks R, Smith-Norowitz T, et al. Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma. J Antimicrob Chemother 2013; 68:2363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzo A, Domenico MD, Carratelli CR, Paolillo R. The role of Chlamydia and Chlamydophila infections in reactive arthritis. Intern Med 2012; 51:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melby KK, Kvien TK, Glennås A, Anestad G. Chlamydia pneumoniae as a trigger of reactive arthritis. Scand J Infect Dis 1999; 31:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter JD, Hudson AP. The evolving story of Chlamydia-induced reactive arthritis. Curr Opin Rheumatol 2010; 22:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falsey AR, Walsh EE. Transmission of Chlamydia pneumoniae. J Infect Dis 1993; 168:493.
          </a>
         </li>
         <li class="breakAll">
          Siegel JD, Rhinehart E, Jackson M, et al. Healthcare Infection Control Practices Advisory Committee 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, June 2007. Updated July 2019. https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html (Accessed on October 27, 2021).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5957 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=83558&amp;lvl=3&amp;lin=f&amp;keep=1&amp;srchmode=1&amp;unlock" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Center for Biotechnology InformationTaxonomy Browser. Accessed May 10, 2017. https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=83558&amp;lvl=3&amp;lin=f&amp;keep=1&amp;srchmode=1&amp;unlock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10319462" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27995871" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : International Committee on Systematics of Prokaryotes Subcommittee on the taxonomy of Chlamydiae. Minutes of the closed meeting, 31 March 2015, New Orleans, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25670734" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The role of peptidoglycan in chlamydial cell division: towards resolving the chlamydial anomaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171546" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Chlamydophila pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23218799" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Chlamydia pneumoniae: modern insights into an ancient pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23218799" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Chlamydia pneumoniae: modern insights into an ancient pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23218799" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Chlamydia pneumoniae: modern insights into an ancient pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17243062" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25988545" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pneumonia Outbreak Caused by Chlamydophila pneumoniae among US Air Force Academy Cadets, Colorado, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17080373" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Outbreak of Chlamydia pneumoniae infection in a Japanese nursing home, 1999-2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23723194" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Investigation of a Chlamydia pneumoniae outbreak in a Federal correctional facility in Texas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12192165" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence, rate of persistence and respiratory tract symptoms of Chlamydia pneumoniae infection in 1211 kindergarten and school age children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10048679" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Etiology and treatment of community-acquired pneumonia in ambulatory children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15060215" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19670403" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Role of Chlamydophila pneumoniae in children hospitalized for community-acquired pneumonia in Vienna, Austria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25714161" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Community-acquired pneumonia requiring hospitalization among U.S. children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28129377" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : High Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in Children with Acute Respiratory Infections from Lima, Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7746693" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Infection with Chlamydia pneumoniae in infants and children with acute lower respiratory tract disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11303262" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2010629" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Infection with Chlamydia pneumoniae in Brooklyn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11044570" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The use of serologic tests for the diagnosis of chlamydial infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11044570" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The use of serologic tests for the diagnosis of chlamydial infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15917413" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15917413" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1774340" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1500751" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7667050" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9194103" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prevalence of Chlamydia pneumoniae in healthy children and in children with respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9510442" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Chlamydia pneumoniae in children with acute respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8019629" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The association of Chlamydia pneumoniae infection and reactive airway disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2372005" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chlamydia pneumoniae strain TWAR, Mycoplasma pneumoniae, and viral infections in acute respiratory disease in a university student health clinic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16316495" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10476753" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3335808" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951390" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Chlamydia pneumoniae pneumonia with pleural effusion: diagnosis by culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15635034" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Acute hemorrhagic pericarditis in a child with pneumonia due to Chlamydophila pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12065338" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8228356" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8218684" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : An epidemic of infections due to Chlamydia pneumoniae in military conscripts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11054150" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Meningoencephalitis and Chlamydia pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10619758" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Severe meningoencephalitis: an unusual manifestation of Chlamydia pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8028636" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Chlamydia pneumonia and meningoencephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1732807" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Guillain-Barrésyndrome after Chlamydia pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18953592" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Chlamydophila pneumoniae myopericarditis in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26338247" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A case of interstitial pneumonia, myocarditis and severe sepsis caused by Chlamydia pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17204998" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Co-infection with two Chlamydophila species in a case of fulminant myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16156318" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Early detection and successful therapy of fulminant chlamydia pneumoniae myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7658858" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Chlamydia pneumoniae myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29955859" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28159161" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28159161" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29593057" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Multicenter Evaluation of BioFire FilmArray Respiratory Panel 2 for Detection of Viruses and Bacteria in Nasopharyngeal Swab Samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30502640" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29212701" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660863" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Multiplexed detection and identification of respiratory pathogens using the NxTAG®respiratory pathogen panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8027341" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21880587" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21880587" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32525203" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25579069" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Treatment of Chlamydial infections: 2014 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30509942" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : In Vitro Activity of Omadacycline against Chlamydia pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802626" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15231980" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The Use of Systemic and Topical Fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10724028" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Therapeutic effect of clarithromycin for respiratory-tract infections in children caused by Chlamydia pneumoniae. Research Group of Sapporo for Pediatric Chlamydial Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18327427" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9449287" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10854812" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10819727" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30619180" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Chlamydia Persistence: A Survival Strategy to Evade Antimicrobial Effects in-vitro and in-vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10482058" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae and persistent cough in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724797" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Detection of Chlamydophila Pneumoniae and Typical Bacteria in Patients with Chronic Cough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10093951" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : An epidemic of a pertussis-like illness caused by Chlamydia pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9063543" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Prevalence of positive serology for acute Chlamydia pneumoniae infection in emergency department patients with persistent cough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18070131" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Acute Chlamydia pneumoniae infections in asthmatic and non-asthmatic military conscripts during a non-epidemic period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24429432" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Chlamydia pneumoniae: possible association with asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29755754" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Chlamydia pneumoniae-induced tumour necrosis factor alpha responses are lower in children with asthma compared with non-asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23749949" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22214635" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The role of Chlamydia and Chlamydophila infections in reactive arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10482071" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Chlamydia pneumoniae as a trigger of reactive arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20445454" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The evolving story of Chlamydia-induced reactive arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8335994" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Transmission of Chlamydia pneumoniae.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
